| Kristen Macdougall Bybee, AUD | |
|
1200 Childrens Ave # 8c, Oklahoma City, OK 73104-4637 | |
| (405) 271-2662 | |
| Not Available |
| Full Name | Kristen Macdougall Bybee |
|---|---|
| Gender | Female |
| Speciality | |
| Experience | Years |
| Location | 1200 Childrens Ave # 8c, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023682135 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 5551 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kristen Macdougall Bybee, AUD 825 Ne 10th St Ste 4200, Oklahoma City, OK 73104-5417 Ph: (405) 271-1368 | Kristen Macdougall Bybee, AUD 1200 Childrens Ave # 8c, Oklahoma City, OK 73104-4637 Ph: (405) 271-2662 |
News Archive
The U.S. Food and Drug Administration today cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, called OVA1, helps patients and health care professionals decide what type of surgery should be done and by whom.
When it comes to tanning, dermatologists have long suspected that most people need an attitude adjustment. Now, results of a new survey by the American Academy of Dermatology (Academy) confirmed that the majority of people still idolize the bronzed look of a tan despite wanting to protect themselves from skin cancer.
QRxPharma announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. Required for New Drug Application submission with the United States Food and Drug Administration, this "combination rule" study compared the efficacy and safety profiles of MoxDuo IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery.
Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, demonstrate that Zometa (zoledronic acid), an intravenous bisphosphonate, was shown to inhibit bone loss in postmenopausal women treated with Femara (letrozole) in the adjuvant breast cancer setting (directly following surgery to prevent cancer recurrence).
Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research.
› Verified 9 days ago
Mrs. Farris Ree Stroupe, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 4140 W. Memorial Rd Suite 116, Oklahoma City, OK 73120 Phone: 405-755-1930 | |
Kerri Anne Conley, M.S. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 3400 Nw 56th St, Oklahoma City, OK 73112 Phone: 405-949-1906 | |
Dr. Elizabeth Ann Harder, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 535 Nw 9th St, Suite 305, Oklahoma City, OK 73102 Phone: 405-272-6027 | |
Ms. Esther H Kim, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 11500 N Portland Ave, Oklahoma City, OK 73120 Phone: 405-548-4300 Fax: 405-548-4349 | |
Dr. Elizabeth Ruth Elliott, AU.D., M.B.A. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 921 Ne 13th St, Oklahoma City, OK 73104 Phone: 405-270-0501 Fax: 405-552-4365 | |
Jace A Wolfe, PHD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 11500 N Portland Ave, Oklahoma City, OK 73120 Phone: 405-548-4300 |